Martin Cheever
Medical Oncology · Seattle, WANPI 1356562250
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,017 of the $3,017 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Gilead.
Across 1 payment — averaging $3017.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
Across 47 payments — averaging $88,741 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$2.4M
- Merck$1.2M
- Genentech, Inc.$553K
- Dendreon Pharmaceuticals LLC$67K
What the payments were for
- Consulting fees$3,017100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 1 | $3,017 |
How this compares
$3,017 in reported general payments places this provider in the 55th percentile of 162 medical oncology providers in Washington.
Other medical oncology in Seattle
- Bart ScottSeattle$1.3M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Rafic FarahSeattle$114K
- Laura ChowSeattle$114K
- Shailender BhatiaSeattle$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.